Cited 0 times in Scipus Cited Count

PROPIT: A PROspective comparative clinical study evaluating the efficacy and safety of PITavastatin in patients with metabolic syndrome.

DC Field Value Language
dc.contributor.authorChoi, SH-
dc.contributor.authorLim, S-
dc.contributor.authorHong, ES-
dc.contributor.authorSeo, JA-
dc.contributor.authorPark, CY-
dc.contributor.authorNoh, JH-
dc.contributor.authorMok, JO-
dc.contributor.authorLee, KY-
dc.contributor.authorPark, JS-
dc.contributor.authorKim, DJ-
dc.contributor.authorLee, CB-
dc.contributor.authorKim, SR-
dc.contributor.authorJang, HC-
dc.date.accessioned2017-01-31T04:43:21Z-
dc.date.available2017-01-31T04:43:21Z-
dc.date.issued2015-
dc.identifier.issn0300-0664-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/13428-
dc.description.abstractOBJECTIVE: Dyslipidaemia and central obesity are the major factors underlying the dramatic increase in metabolic syndrome (MS). We compared the effects of early combined therapy with pitavastatin and intensive lifestyle modification (LSM) on the amelioration of each component of MS with those of LSM only.

DESIGN/PARTICIPANTS/MEASUREMENTS: PROPIT (a PROspective comparative clinical study to evaluate the efficacy and safety of PITavastatin in patients with metabolic syndrome) was a prospective, randomized, multicenter open-label 48-week trial. We enrolled 187 patients with MS (central obesity and prediabetes) and randomized them into two treatment groups: 2 mg pitavastatin daily + intensive LSM or intensive LSM only. The primary outcome was the improvements in the components of MS and in the percentage of non-MS converters.

RESULTS: After 1 year treatment, the improvement of MS score was significantly higher in the pitavastatin + LSM group (P = 0·039). However, non-MS converters (MS score ≤2) did not differ between the groups. The secondary outcomes, namely lipid profiles, the Apo B/A1 ratio, visceral fat/subcutaneous fat ratio and the Framingham risk score, were significantly improved in the pitavastatin group. There was no deterioration in glucose metabolism after treatment with pitavastatin for 1 year.

CONCLUSIONS: Early statin treatment can be an effective option in obese patients with MS, prediabetes and mild dyslipidaemia with further improvement of cardiovascular risk factors. We could not observe the increase rate of glucose intolerance in statin group. Future longitudinal studies are needed to test the benefits of early statin treatment compared with LSM.
-
dc.language.isoen-
dc.subject.MESHAdolescent-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHBlood Glucose-
dc.subject.MESHBody Weight-
dc.subject.MESHCardiovascular Diseases-
dc.subject.MESHDyslipidemias-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHHydroxymethylglutaryl-CoA Reductase Inhibitors-
dc.subject.MESHLife Style-
dc.subject.MESHLipids-
dc.subject.MESHMale-
dc.subject.MESHMetabolic Syndrome X-
dc.subject.MESHMiddle Aged-
dc.subject.MESHProspective Studies-
dc.subject.MESHQuinolines-
dc.subject.MESHRisk Factors-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHYoung Adult-
dc.titlePROPIT: A PROspective comparative clinical study evaluating the efficacy and safety of PITavastatin in patients with metabolic syndrome.-
dc.typeArticle-
dc.identifier.pmid25109606-
dc.contributor.affiliatedAuthor김, 대중-
dc.type.localJournal Papers-
dc.identifier.doi10.1111/cen.12580-
dc.citation.titleClinical endocrinology-
dc.citation.volume82-
dc.citation.number5-
dc.citation.date2015-
dc.citation.startPage670-
dc.citation.endPage677-
dc.identifier.bibliographicCitationClinical endocrinology, 82(5). : 670-677, 2015-
dc.identifier.eissn1365-2265-
dc.relation.journalidJ003000664-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Endocrinology & Metabolism
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse